While the findings from the most recent CARD study prove promising, it's the toxicity results that have one expert excited.
The phase IV clinical trial known as the CARD study presented new findings at the European Society of Medical Oncology (ESMO) 2019 congress. The trial compared the chemotherapy agent cabzitaxel (Jevtana) and an androgen receptor, either abiraterone (Zytiga) or enzalutamide (Xtandi), in a randomized group of patients with advanced prostate cancer.
The results proved promising for treating advanced prostate cancer with manageable toxicity. At ESMO OncLive®, a sister publication of Oncology Nursing News® had the chance to sit down with Arash Rezazadeh Kalebasty, MD, medical oncologist at the Norton Cancer Institute, to discuss the findings of the CARD study in relation to toxicity.
One important outcome was grade 3 and more toxicity, which was not really very much higher than the androgen therapy arm. I think it's very encouraging because in this patient population toxicity matters as a lot of patients with advanced prostate cancer are elderly. So, specifics for this trial had excluded patients who were not a good candidate for chemotherapy anyways, but we have to be careful about benefit versus risk when we offer patients chemotherapy as well.